Becker ML - Search Results

1

Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.

Becker ML, Visser LE, Trienekens PH, Hofman A, van Schaik RH, Stricker BH. Becker ML, et al. Clin Pharmacol Ther. 2008 Feb;83(2):288-92. doi: 10.1038/sj.clpt.6100273. Epub 2007 Jun 27. Clin Pharmacol Ther. 2008. PMID: 17597710

2

Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus.

Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Becker ML, et al. Pharmacogenomics J. 2009 Aug;9(4):242-7. doi: 10.1038/tpj.2009.15. Epub 2009 Apr 21. Pharmacogenomics J. 2009. PMID: 19381165

3

Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylurea.

Becker ML, Aarnoudse AJ, Newton-Cheh C, Hofman A, Witteman JC, Uitterlinden AG, Visser LE, Stricker BH. Becker ML, et al. Pharmacogenet Genomics. 2008 Jul;18(7):591-7. doi: 10.1097/FPC.0b013e328300e8c5. Pharmacogenet Genomics. 2008. PMID: 18551039

4

A common NOS1AP genetic polymorphism is associated with increased cardiovascular mortality in users of dihydropyridine calcium channel blockers.

Becker ML, Visser LE, Newton-Cheh C, Hofman A, Uitterlinden AG, Witteman JC, Stricker BH. Becker ML, et al. Br J Clin Pharmacol. 2009 Jan;67(1):61-7. doi: 10.1111/j.1365-2125.2008.03325.x. Epub 2008 Nov 17. Br J Clin Pharmacol. 2009. PMID: 19076153 Free PMC article.

5

Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study.

Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Becker ML, et al. Diabetes. 2009 Mar;58(3):745-9. doi: 10.2337/db08-1028. Epub 2009 Feb 19. Diabetes. 2009. PMID: 19228809 Free PMC article.

6

Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response.

Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Becker ML, et al. Pharmacogenet Genomics. 2010 Jan;20(1):38-44. doi: 10.1097/FPC.0b013e328333bb11. Pharmacogenet Genomics. 2010. PMID: 19898263

7

Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy.

Becker ML, Elens LL, Visser LE, Hofman A, Uitterlinden AG, van Schaik RH, Stricker BH. Becker ML, et al. Pharmacogenomics J. 2013 Jun;13(3):251-6. doi: 10.1038/tpj.2011.59. Epub 2011 Dec 20. Pharmacogenomics J. 2013. PMID: 22186618

8

Increasing exposure to drug-drug interactions between 1992 and 2005 in people aged > or = 55 years.

Becker ML, Visser LE, van Gelder T, Hofman A, Stricker BH. Becker ML, et al. Drugs Aging. 2008;25(2):145-52. doi: 10.2165/00002512-200825020-00006. Drugs Aging. 2008. PMID: 18257601

9

Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy.

Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Becker ML, et al. Pharmacoepidemiol Drug Saf. 2010 Jan;19(1):75-81. doi: 10.1002/pds.1866. Pharmacoepidemiol Drug Saf. 2010. PMID: 19802823

10

Common genetic variation in the ABCB1 gene is associated with the cholesterol-lowering effect of simvastatin in males.

Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Becker ML, et al. Pharmacogenomics. 2009 Nov;10(11):1743-51. doi: 10.2217/pgs.09.105. Pharmacogenomics. 2009. PMID: 19891551

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

384 results

Search Page

Filters